LErafAON

Drug Profile

LErafAON

Alternative Names: LE-AON; LE-rafAON; LErafAON-ETU; Liposomal encapsulated antisense oligonucleotide c-raf-1

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Georgetown University
  • Developer INSYS Therapeutics, Inc
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Antisense RNA inhibitors; Proto oncogene proteins c raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 18 Oct 2016 Discontinued - Preclinical for Solid tumours in USA (IV)
  • 05 Mar 2009 Preclinical development is ongoing in USA
  • 31 Dec 2006 Discontinued - Phase-I for Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top